ProCE Banner Activity

HPTN 077: No Significant Weight Gain at Week 41 With Long-Acting CAB vs PBO in HIV-Uninfected Persons at Low Risk for Infection

Slideset Download
Conference Coverage
Post hoc analysis finds no evidence of association between cabotegravir use and weight gain.

Released: March 11, 2019

Expiration: March 09, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare